Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast overshadowed beats on revenue and earnings per share (EPS).
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the company’s full-year revenue guidance of $695 million at the midpoint came in 1.1% below analysts’ estimates. Its GAAP loss of $0.80 per share was 13.7% above analysts’ consensus estimates.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $192.1 million. On the other hand, the company’s full-year revenue guidance of $695 million at the midpoint came in 1.1% below analysts’ estimates. Its GAAP profit of $0.80 per share was significantly above analysts’ consensus estimates.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best and worst performers in the branded pharmaceuticals industry.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
will be reporting earnings this Tuesday after market hours. Here’s what you need to know.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Supernus Pharmaceuticals (SUPN) is a strong growth stock with a debt-free balance sheet and a positive technical breakout pattern. Explore its potential.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
jumped 4.6% in the morning session after Piper Sandler upgraded the company's stock from a "Neutral" to an "Overweight" rating and raised its price target.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.
Supernus Pharmaceuticals (SUPN) offers affordable growth with strong earnings, a clean balance sheet, and an attractive P/E ratio below industry peers.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q2.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
SUPERNUS (SUPN) offers affordable growth with strong EPS & revenue expansion, solid profitability, and a sound financial base, all at a discount to the pharmaceutical industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst performers in the branded pharmaceuticals industry.
